RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Fischer, Julius C
MetadataShow full item record
AbstractAntibody-mediated targeting of regulatory T cell receptors such as CTLA-4 enhances antitumor immune responses against several cancer entities including malignant melanoma. Yet, therapeutic success in patients remains variable underscoring the need for novel combinatorial approaches. Here we established a vaccination strategy that combines engagement of the nucleic acid-sensing pattern recognition receptor RIG-I, antigen and CTLA-4 blockade. We used in vitro transcribed 5'-triphosphorylated RNA (3pRNA) to therapeutically target the RIG-I pathway. We performed in vitro functional analysis in bone-marrow derived dendritic cells and investigated RIG-I-enhanced vaccines in different murine melanoma models. We found that protein vaccination together with RIG-I ligation via 3pRNA strongly synergizes with CTLA-4 blockade to induce expansion and activation of antigen-specific CD8 Overall, our data demonstrate the potency of a novel combinatorial vaccination strategy combining RIG-I-driven immunization with CTLA-4 blockade to prevent and treat experimental melanoma. FUND: German Research Foundation (SFB 1335, SFB 1371), EMBO, Else Kröner-Fresenius-Foundation, German Cancer Aid, European Hematology Association, DKMS Foundation for Giving Life, Dres. Carl Maximilian and Carl Manfred Bayer-Foundation.
AffiliationTWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH, Feodor-Lynen-Str.7,30625 Hannover, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- RIG-I activation is critical for responsiveness to checkpoint blockade.
- Authors: Heidegger S, Wintges A, Stritzke F, Bek S, Steiger K, Koenig PA, Göttert S, Engleitner T, Öllinger R, Nedelko T, Fischer JC, Makarov V, Winter C, Rad R, van den Brink MRM, Ruland J, Bassermann F, Chan TA, Haas T, Poeck H
- Issue date: 2019 Sep 13
- Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
- Authors: Such L, Zhao F, Liu D, Thier B, Le-Trilling VTK, Sucker A, Coch C, Pieper N, Howe S, Bhat H, Kalkavan H, Ritter C, Brinkhaus R, Ugurel S, Köster J, Seifert U, Dittmer U, Schuler M, Lang KS, Kufer TA, Hartmann G, Becker JC, Horn S, Ferrone S, Liu D, Van Allen EM, Schadendorf D, Griewank K, Trilling M, Paschen A
- Issue date: 2020 Aug 3
- Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
- Authors: Foy SP, Mandl SJ, dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A, Rountree RB
- Issue date: 2016 May
- PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy.
- Authors: Koerner J, Horvath D, Herrmann VL, MacKerracher A, Gander B, Yagita H, Rohayem J, Groettrup M
- Issue date: 2021 May 18
- Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
- Authors: Rausch J, Lopez PA, Bialojan A, Denny M, Langguth P, Probst HC, Schild H, Radsak MP
- Issue date: 2017 Sep